Thus, although the prognostic value of BRAF has been analysed in CRC patients treated with specific chemotherapy regimens, it remains unclear what impact the KRAS12, KRAS13, and BRAF mutations have on clinical outcomes of all patients with advanced or recurrent CRC treated with systemic treatments. This evidence concerns the gene BRAF and colorectal carcinoma.